Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Biotechnology

Healthcare
$39.15 +8.79%

+$2.32 today

Market cap
$1.83B
Beta
0.00
52W Low $23.00High $36.61

Volume 0.30M

Average 0.34M

COAG Acquisitions (Net)

Cash paid for acquiring businesses, net of cash acquired.

Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG

Acquisitions (Net) · Q2 FY2026 · quarter ended Jun 2026

Acquisitions (net) of $0 in Q2 FY2026

Q2 FY2026 acquisitions (net) was $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Acquisitions (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Acquisitions (Net) history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Acquisitions (Net) vs competitors

How COAG compares with its peers on the latest reported figures

  • COAG's FY2025 acquisitions (net) of $0 is the 3rd largest of the 5 companies compared; the peer median is $41.5K.
COAG Competitors Peer median
Acquisitions (Net) for COAG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RLYBRallybio CorporationLTM Mar 2026$20M +8100.0%—2331.0%
DMRADamora Therapeutics, Inc.LTM Jun 2024$83K ———
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025$0 ———
IRONDisc Medicine, Inc.LTM Sep 2026$0 ———
QUREuniQure N.V.LTM Mar 2026$0 ——0.0%
Peer median (excluding COAG) $41.5K+8100.0%—1165.5%

Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Hemab Therapeutics Holdings, Inc. Common Stock

NASDAQ:COAG

Intrinsic Alpha fair value

Locked

Current Price

$39.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.